Atea Pharmaceuticals is trading at $4.24, down 5.04%, with no clear company-specific catalyst identified.
- Atea Pharmaceuticals’ investor-relations news page lists no release dated October 20 or 21; its latest release is September 8.
- The biotech sector and major U.S. indexes are higher, so broader-market strength does not explain the October 21 decline.
- Trading volume or activity-level details were unavailable in the provided price context.